Shipping to United States We Offer Worldwide Shipping
Login Wishlist

Gardoside

$480

  • Brand : BIOFRON

  • Catalogue Number : BD-D1261

  • Specification : 98%(HPLC)

  • CAS number : 54835-76-6

  • Formula : C16H22O10

  • Molecular Weight : 374.34

  • PUBCHEM ID : 46173850

  • Volume : 10MG

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-D1261

Analysis Method

HPLC,NMR,MS

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

374.34

Appearance

Powder

Botanical Source

Structure Type

Monoterpenoids

Category

SMILES

C=C1C(CC2C1C(OC=C2C(=O)O)OC3C(C(C(C(O3)CO)O)O)O)O

Synonyms

(1S,4aS,6S,7aS)-6-hydroxy-7-methylidene-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,5,6,7a-tetrahydro-1H-cyclopenta[c]pyran-4-carboxylic acid

IUPAC Name

(1S,4aS,6S,7aS)-6-hydroxy-7-methylidene-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,5,6,7a-tetrahydro-1H-cyclopenta[c]pyran-4-carboxylic acid

Applications

Density

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

Boiling Point

Melting Point

InChl

InChI=1S/C16H22O10/c1-5-8(18)2-6-7(14(22)23)4-24-15(10(5)6)26-16-13(21)12(20)11(19)9(3-17)25-16/h4,6,8-13,15-21H,1-3H2,(H,22,23)/t6-,8+,9-,10-,11-,12+,13-,15+,16+/m1/s1

InChl Key

JSKCJJNYSGWZDU-RQJSCMEKSA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:54835-76-6) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

24427090

Abstract

Refluxing a mixture of 1,10-phenanthroline, (4-fluoro­phen­yl)thio­urea and cadmium(II) chloride did not produce the expected mixed-ligand complex but formed a co-crystal of the two ligands, C12H8N2·C7H7FN2S. The asymmetric unit consists of two pairs of the co-crystal mol­ecules. In each (4-fluoro­phen­yl)thio­urea mol­ecule, the planes of the N2CS thio­urea units are almost perpendicular to the corresponding fluoro­benzene rings, subtending angles of 76.53 (7) and 85.25 (7)°. In the crystal, N—H⋯N and N—H⋯S hydrogen bonds form inversion dimers from the co-crystal pairs. A weak π-π inter­action between the phenanthroline rings [centroid-centroid distance = 3.7430 (15)a] is also observed.

Title

(4-Fluoro­phen­yl)thio­urea-1,10-phenanthroline (1/1)

Author

Bohari M. Yamin,a Halima F. Salem,a and Siti Fairus M. Yusoffa,*

Publish date

2013 Sep 1;

PMID

26517707

Abstract

RNA editing is the post-transcriptional conversion from C to U before translation, providing a unique feature in the regulation of gene expression. Here, we used a robust and efficient method based on RNA-seq from non-ribosomal total RNA to simultaneously measure chloroplast-gene expression and RNA editing efficiency in the Greater Duckweed, Spirodela polyrhiza, a species that provides a new reference for the phylogenetic studies of monocotyledonous plants. We identified 66 editing sites at the genome-wide level, with an average editing efficiency of 76%. We found that the expression levels of chloroplast genes were relatively constant, but 11 RNA editing sites show significant changes in editing efficiency, when fronds turn into turions. Thus, RNA editing efficiency contributes more to the yield of translatable transcripts than steady state mRNA levels. Comparison of RNA editing sites in coconut, Spirodela, maize, and rice suggests that RNA editing originated from a common ancestor.

Title

RNA Editing in Chloroplasts of Spirodela polyrhiza, an Aquatic Monocotelydonous Species

Author

Wenqin Wang, Wei Zhang, Yongrui Wu, ¤ Pal Maliga, and Joachim Messing*

Publish date

2015;

PMID

19821293

Abstract

Background
Dysmenorrhoea (painful menstrual cramps) is common. Combined OCPs are recommended in the management of primary dysmenorrhoea.

Objectives
To determine the effectiveness and safety of combined oral contraceptive pills for the management of primary dysmenorrhoea.

Search methods
We conducted electronic searches for randomised controlled trials (RCTs) in the Cochrane Menstrual Disorders and Subfertility Group Register of controlled trials CENTRAL, CCTR, MEDLINE, EMBASE, and CINAHL (first conducted in 2001, updated on 5 November 2008).

Selection criteria
RCTs comparing all combined OCPs with other combined OCPs, placebo, no management, or management with nonsteroidal anti‐inflammatories (NSAIDs) were considered.

Data collection and analysis
Twenty three studies were identified and ten were included. Six compared the combined OCP with placebo and four compared different dosages of combined OCP.

Main results
One study of low dose oestrogen and four studies of medium dose oestrogen combined OCPs compared with placebo, for a combined total of 497 women, reported pain improvement. For the outcome of pain relief across the different OCPs the pooled OR suggested benefit with OCPs compared to placebo (7 RCTs: Peto OR 2.01 [95% CI 1.32, 3.08]).The Chi‐squared test for heterogeneity showed there is significant heterogeneity with an I2 statistic of 64% and a significant chi‐square test (14.06, df=5, p=0.02). A sensitivity analysis removing the studies with inadequate allocation concealment suggested significant benefit of treatment with the pooled OR of 2.99 (95% CI 1.76, 5.07) and heterogeneity no longer statistically significant and I2 statistic of 0%.

Three studies reported adverse effects (Davis 2005; Hendrix 2002; GPRG 1968) The adverse effects were nausea, headaches and weight gain. Two studies reported if women experienced any side effect and no evidence of an effect was found (3 RCTs: OR = 1.45 (95% 0.71, 2.94). There was no evidence of statistical heterogeneity.

There were no studies identified that compared combined OCP versus non steroidal anti‐inflammatory drugs

There was no evidence of a difference for the pooled studies for 3rd generation pro gestagens (OR = 1.11 (95% CI 0.79 ‐ 1.57)). For the 2nd generation versus 3rd generation the OR was 0.44 (95% CI 0.23‐0.84) suggesting benefit of the 3rd generation OCP but this was for a single study (Winkler 2003).

Authors’ conclusions
There is limited evidence for pain improvement with the use of the OCP (both low and medium dose oestrogen) in women with dysmenorrhoea. There is no evidence of a difference between different OCP preparations.

Title

Oral contraceptive pill for primary dysmenorrhoea

Author

Monitoring Editor: Chooi L Wong,corresponding author Cindy Farquhar, Helen Roberts, Michelle Proctor, and Cochrane Gynaecology and Fertility Group

Publish date

2009 Oct